Cancer Research UK and Vaccitech Oncology Limited (VOLT), announced Wednesday that a new partnership to bring a novel immunotherapeutic vaccine strategy to patients with lung cancer. The vaccine treatment developed by VOLT, a strategic collaboration between Vaccitech Ltd and the Ludwig Institute for Cancer Research, is designed to stimulate the body’s immune system to attack cancer cells. It will deliver cancer-associated antigens (MAGE A3 and NY-ESO-1) to antigen presenting cells called dendritic cells, causing the immune system to produce cytotoxic T cells, which target and kill cancerous cells expressing the antigens.
To learn more, go to: https://www.cancerresearchuk.org/about-us/cancer-news/press-release/2019-12-17-first-in-human-trial-for-new-lung-cancer-immunotherapy
